143 related articles for article (PubMed ID: 20649944)
21. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
[TBL] [Abstract][Full Text] [Related]
23. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
Diago M; Castellano G; García-Samaniego J; Pérez C; Fernández I; Romero M; Iacono OL; García-Monzón C
Gut; 2006 Mar; 55(3):374-9. PubMed ID: 16150856
[TBL] [Abstract][Full Text] [Related]
24. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
25. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
26. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
27. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
[TBL] [Abstract][Full Text] [Related]
29. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
Oze T; Hiramatsu N; Yakushijin T; Kurokawa M; Igura T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Yoshida Y; Tatsumi T; Ohkawa K; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2009 Aug; 16(8):578-85. PubMed ID: 19552663
[TBL] [Abstract][Full Text] [Related]
30. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.
Males S; Gad RR; Esmat G; Abobakr H; Anwar M; Rekacewicz C; El Hoseiny M; Zalata K; Abdel-Hamid M; Bedossa P; Pol S; Mohamed MK; Fontanet A
Antivir Ther; 2007; 12(5):797-803. PubMed ID: 17713163
[TBL] [Abstract][Full Text] [Related]
31. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
33. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.
Loftfield E; O'Brien TR; Pfeiffer RM; Howell CD; Horst R; Prokunina-Olsson L; Weinstein SJ; Albanes D; Morgan TR; Freedman ND
PLoS One; 2016; 11(11):e0166036. PubMed ID: 27832143
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials.
Kim HB; Myung SK; Lee YJ; Park BJ;
J Hum Nutr Diet; 2018 Apr; 31(2):168-177. PubMed ID: 28833855
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D deficiency and hepatitis viruses-associated liver diseases: A literature review.
Hoan NX; Tong HV; Song LH; Meyer CG; Velavan TP
World J Gastroenterol; 2018 Jan; 24(4):445-460. PubMed ID: 29398866
[TBL] [Abstract][Full Text] [Related]
37. Interplay between vitamin D status and antiviral therapy among chronic hepatitis C Egyptian patients.
Abd Elalim MH; Zaky DZ; Motawae IA; Mohamed NA; Nagib AN
J Egypt Soc Parasitol; 2015 Apr; 45(1):17-22. PubMed ID: 26012214
[TBL] [Abstract][Full Text] [Related]
38. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C.
Ladero JM; Torrejón MJ; Sánchez-Pobre P; Suárez A; Cuenca F; de la Orden V; Devesa MJ; Rodrigo M; Estrada V; López-Alonso G; Agúndez JA
Ann Hepatol; 2013; 12(2):199-204. PubMed ID: 23396730
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C infected patients need vitamin D3 supplementation in the era of direct acting antivirals treatment.
Kondo Y
World J Gastroenterol; 2017 Feb; 23(8):1325-1327. PubMed ID: 28293078
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?
Jin CN; Chen JD; Sheng JF
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):741-746. PubMed ID: 29664746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
